Navigation Links
UC to test targeted treatment for prostate cancer
Date:4/16/2010

CINCINNATIThe American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.

In the study, UC researchers in the lab of Zhongyun Dong, PhD, will test the efficacy of a new agent targeted against a specific protein on the surface of the tumor.

"It's been shown that human prostate cancer cells overexpress some proteins on their surface," says Dong, an associate professor of hematology oncology in the department of internal medicine. "This overexpression presents a novel target for management of advanced prostate cancer."

Dong says previous radiation therapy targeting these proteins has been shown to inhibit tumor growth in several animal models. UC's study will be the first to explore this approach for prostate tumors. In the work, researchers will bind the isotope 212-lead to an antibody targeting one of these proteins.

"When administered intravenously, the AREVA Med 2120lead-antibody is designed to bind to the tumor's surface, emit alpha particles in and selectively destroy the tumor cells," says Dong.

In the study, expected to run through the end of the year, researchers will measure the toxicity of the treatment and its efficacy in inhibiting cancer cell growth. Data will then be gathered to support phase-1 clinical trials in patients with advanced prostate cancer.

According to hematology oncology professor Olivier Rixe, MD, PhD, the agent represents a more targeted radiation therapy for cancer treatment. Rixe is the director of the UC's recently launched phase-1 clinical trials unit at the newly established Early Drug Development Program.

"Targeting a monoclonal antibody against this protein is not new," says Rixe. "What's new is that we will load the antibody with an isotope that can directly target the protein on the cancer cell and deliver very localized radiation to this specific target of the cancer.

"It's a very interesting concept for drug delivery and a novel strategy for cancer treatment."


'/>"/>

Contact: Katy Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Related biology news :

1. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
2. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
3. Researchers combat slowing yields with targeted fertilizer applications
4. Fishing throws targeted species off balance, Scripps study shows
5. New technique allows targeted inactivation of genes in research model
6. Newly identified role for power plants in human cells could lead to targeted therapies
7. Consortium develops new method enabling routine targeted gene modification
8. On the trail of a targeted therapy for blood cancers
9. Cellular discovery may lead to targeted treatment for rare form of anemia
10. Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment
11. Targeted drug therapy prevents exercise-induced arrhythmias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology: